Status: Recruiting
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
Participants needed: 474
Trial details
Phase: Phase 3Age: 12-12Biological sex: AllType: InterventionalSponsor: GC Biopharma CorpUpdated: Apr 17, 2026Locations: 1
Eligibility criteria
Participant must be 12 months to 12 years of age, inclusive, at the time of sign... [+1]
Participants with a history of exposure to varicella through contact with a vari... [+3]